MedTrace Logo

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

NCT05434585 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-02-08

No results posted yet for this study

Summary

A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection. this study is conducted during Indonesian subjects aged 18 years and older who have not received SARS-CoV-2 vaccines.

Conditions

Interventions

BIOLOGICAL

ABO1009-DP

Vaccine

BIOLOGICAL

ABO-CoV.617.2

Vaccine

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Suzhou Abogen Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dingfeng Wu · Suzhou Abogen Biosciences Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-08
Primary Completion
2022-10-10
Completion
2023-08-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434585 on ClinicalTrials.gov